Skip to content

D&A at other companies

Haemonetics logo
HaemoneticsHAE
$27.32M-3.2%
Medtronic logo
MedtronicMDT
$716M-14.8%
ITG
Integer HoldingsITGR
$35.01M+17.4%
ResMed logo
ResMedRMD
$58.98M+35.0%
Boston Scientific logo
Boston ScientificBSX
$351M+8.0%
Merit Medical Systems logo
Merit Medical SystemsMMSI
$30.5M+4.1%

Other financials

Income statement

See full
Revenue$362.3M+14.3%
Gross profit$243.7M+12.7%
Operating income$41.5M-14.7%
Net income$22.3M+107%
EPS (diluted)$0.40+107%

Balance sheet

See full
Cash & equivalents$539.7M-26.9%
Total debt$340.9M-49.7%
Total equity$1.2B+17.1%
Total assets$2.5B-1.7%

Cash flow

See full
Operating cash flow$15.2M-36.5%
CapEx$14.3M+32.4%
Free cash flow$926.0K-93.0%

Valuation

See full
Market cap$4.32B+62.8%

Profitability

See full
Gross margin67.5%-0.5pp
Operating margin13.4%+0.8pp
Net margin-16.1%-18.0pp
FCF margin11.2%-0.2pp

Returns & leverage

See full
Return on equity-17.6%-19.5pp
Debt / equity0.3×-0.4×
Current ratio1.3×-0.2×

Where this comes from

Reported directly by LivaNova in its filing.

Tagged under the XBRL concept us-gaap:Depreciation.

The official record: LivaNova’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about LivaNova's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is LivaNova's D&A?
LivaNova (LIVN) reported D&A of $8.3M in Q1 2026.
How has LivaNova's D&A changed year-over-year?
LivaNova's D&A increased by 29.3% year-over-year, from $6.42M to $8.3M.
What is the long-term trend for LivaNova's D&A?
Over 4 years (2021 to 2025), LivaNova's D&A has grown at a 1.9% compound annual growth rate (CAGR), from $26.52M to $28.56M.
What does D&A mean?
Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.